The FRα Frontier: New Pathways in Platinum-Resistant Ovarian Cancer

Discover how the latest breakthroughs in folate receptor alpha (FRα)-targeted antibody-drug conjugates (ADCs) are redefining what’s possible with biomarker-driven therapy! From landmark clinical findings to promising next-generation ADCs, new treatment opportunities are expanding care across the entire FRα biomarker continuum. Join renowned expert faculty as they unpack the latest clinical evidence, share practical pearls for biomarker testing and treatment sequencing, and provide evidence-based strategies for toxicity management that can be immediately applied to deliver more personalized care for patients with platinum-resistant ovarian cancer (PROC).

In this CE Concepts live symposium, expert faculty will review the latest clinical evidence for integrating FRα testing into treatment decision-making as well as practical strategies for selecting and sequencing FRα-targeted ADCs, including anticipating and managing toxicities, to deliver personalized, multidisciplinary care with greater confidence in the rapidly evolving PROC treatment landscape.

At the conclusion of this activity, learners will be able to better:

• Select an ADC therapy for patients with PROC based on FRα expression
• Evaluate current clinical evidence supporting FRα-targeted therapy in the management of PROC
• Apply current treatment sequencing principles to optimize therapeutic decision-making for patients with PROC
• Apply a standardized monitoring and escalation protocol to manage FRα-targeted ADC toxicity in patients with PROC

This activity is supported by an educational grant from Genmab.

Oncologists, nurse practitioners (NPs), and physician associates (PAs)

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Alvarez Secord reports the following financial relationships:

Advisory Boards: AbbVie Inc.; AstraZeneca; Corcept Therapeutics, Incorporated; Daiichi Sankyo, Inc.; Eisai; Inc.; Faeth Therapeutics, Inc.; Foundation Medicine, Inc.; Genmab; Gilead Sciences, Inc.; GSK; HistoSonics; and Medtronic

Consultant: AbbVie Inc.; AstraZeneca; Corcept Therapeutics, Incorporated; Daiichi Sankyo, Inc.; Eisai; Inc.; Faeth Therapeutics, Inc.; Foundation Medicine, Inc.; Genmab; Gilead Sciences, Inc.; GSK; HistoSonics; and Medtronic

Grants (paid to institution): AbbVie Inc.; Aravive, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Ellipses Pharma; Genmab; GSK; I-Mab Biopharma; ImmunoGen, Inc.; Karyopharm; Lilly; Merck & Co., Inc.; OncoQuest/CanariaBio, Inc.; Roche/Genentech, Inc.; Seagen Inc.; TORL BioTherapeutics; VBL Therapeutics; and Zentalis Pharmaceuticals, Inc.

Research Support (paid to institution): AstraZeneca; ImmunoGen; Mersana Therapeutics, Inc.; Myriad; and OncoQuest

Other financial or material support:
Participation on the AAOGF Board of Trustees, FWC Board of Directors, GOG Foundation Board of Directors, Project Nana Medical Advisory Board, and SGO Board of Directors; royalties from UpToDate

Ms. Shaver reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Susan Perry (Planning Committee)
Taylor Wallace, PhD (Planning Committee)
Andrea Perseghin, EdD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.